ISSN 1662-4009 (online)

ey0019.12-13 | Hyperlipidemia | ESPEYB19

12.13. Vaccine targeting ANGPTL3 ameliorates dyslipidemia and associated diseases in mouse models of obese dyslipidemia and familial hypercholesterolemia

Y Fukami H, Morinaga J, Nakagami H, Hayashi H, Okadome Y, Matsunaga E, Kadomatsu T, Horiguchi H, Sato M, Sugizaki T, Kuwabara T, Miyata K, Mukoyama M, Morishita R, Oike

Reports Medicine 2021;2(11):100446. doi: 10.1016/j.xcrm.2021.100446Brief Summary: This mouse study validated a novel, safe treatment with ANGPTL3 peptide vaccine. It was effective to improve obesity-induced dyslipidemia and fatty liver in mice, and also improved dyslipidemia and atherosclerosis in a mouse model of familial hypercholesterolemia, with no reported toxicity.<p class="abste...

ey0018.1-10 | Genetics | ESPEYB18

1.10. MITOL dysfunction causes dwarfism with anterior pituitary hypoplasia

K Matsuno , S Nagashima , I Shiiba , K Taniwaka , K Takeda , T Tokuyama , N Ito , N Matsushita , T Fukuda , S Ishido , R Inatome , S Yanagi

J Biochem. 2020 Sep 1;168(3):305-312. doi: doi: 10.1093/jb/mvaa050. PMID: 32302394.This study shows that mice mitochondrial regulatory gene Mitol-deficient mice display reduced growth in combination with anterior pituitary hypoplasia and reduced growth hormone levels.MITOL encodes a ubiquitin ligase. Ablation of Mitol in nestin-expressing cells ...

ey0018.3-15 | Thyroid Cancer | ESPEYB18

3.15. Lymph node metastasis prediction of papillary thyroid carcinoma based on transfer learning radiomics

J Yu , Y Deng , T Liu , J Zhou , X Jia , T Xiao , S Zhou , J Li , Y Guo , Y Wang , J Zhou , C Chang

Nat Commun. 2020;11:4807. doi: 10.1038/s41467-020-18497-3.This interesting paper illustrates the potential of machine learning to improve the sensitivity and specificity of routine techniques in clinical practice if large cohorts for training and validation of models are used. Yu et al. present a transfer learning model (machine learning approach to solve research problems by r...

ey0018.10-7 | (1) | ESPEYB18

10.7. Circulating metabolites in progression to islet autoimmunity and type 1 diabetes

S Lamichhane , E Kemppainen , K Trošt , H Siljander , H Hyoty , J Ilonen , J Toppari , R Veijola , T Hyotylainen , M Knip , M Orešič

Diabetologia. 2019;62(12):2287–2297. doi: 10.1007/s00125-019-04980-0This study identified different circulatory metabolite profiles in children who subsequently progress to T1D compared to children who progress to islet autoimmunity but not T1D, and antibody-negative control children.In addition to altered T cell immunity and autoantibody appearance, metaboli...

ey0019.3-10 | New genes | ESPEYB19

3.10. GWAS of thyroid dysgenesis identifies a risk locus at 2q33.3 linked to regulation of Wnt signaling

S Narumi , R Opitz , K Nagasaki , K Muroya , Y Asakura , M Adachi , K Abe , C Sugisawa , P Kuhnen , T Ishii , MM Nothen , H Krude , T Hasegawa

Hum Mol Genet. 2022 May 10:ddac093. doi: 10.1093/hmg/ddac093. Online ahead of print. PMID: 35535691Brief Summary: This genome-wide association study (GWAS) of patients with thyroid dysgenesis identified a genetic risk locus for thyroid athyreosis and ectopy. In depth genetic analyses of the disease associated region suggested a new disease mechanism of thyroid dysgenesis mediated by impaired Wnt ...

ey0017.1-6 | Hypopituitarism: Disease Modeling and New Discoveries | ESPEYB17

1.6. Congenital pituitary hypoplasia model demonstrates hypothalamic OTX2 regulation of pituitary progenitor cells

R Matsumoto , H Suga , T Aoi , H Bando , H Fukuoka , G Iguchi , S Narumi , T Hasegawa , K Muguruma , W Ogawa , Y Takahashi

To read the full abstract: J Clin Invest. 2020 Feb 3;130(2):641–654. doi: 10.1172/JCI127378. PMID: 31845906.Congenital pituitary hypoplasia (CPH) is a multifactorial disorder, in which the pituitary has not developed correctly. The underlying mechanisms are mostly unknown, and studies are limited by the lack of appropriate disease models. This work modelled the effect of a novel OTX2</e...

ey0017.7-1 | Clinical Guidance | ESPEYB17

7.1. Anti-Mullerian hormone and letrozole levels in boys with constitutional delay of growth and puberty treated with letrozole or testosterone

E Kohva , T Varimo , H Huopio , S Tenhola , R Voutilainen , J Toppari , PJ Miettinen , K Vaaralahti , J Viinamaki , JT Backman , M Hero , T Raivio

To read the full abstract: Human Reproduction (Oxford, England) vol. 35, 2 (2020): 257–264. doi: https://academic.oup.com/humrep/article/35/2/257/5709207. https://pubmed.ncbi.nlm.nih.gov/31958337/This randomized controlled trial compares treatment with peroral letrozole or intramuscular low-dose testosterone in ...

ey0017.7-8 | Basic Science | ESPEYB17

7.8. Characterization of the human GnRH neuron developmental transcriptome using a GNRH1-TdTomato reporter line in human pluripotent stem cells

C Lund , V Yellapragada , S Vuoristo , D Balboa , S Trova , C Allet , N Eskici , K Pulli , P Giacobini , T Tuuri , T Raivio

To read the full abstract: Disease Models & Mechanisms vol. 13,3 dmm040105. 13 Mar. 2020. doi: https://dmm.biologists.org/content/13/3/dmm040105.longThese authors developed an in vitro model to study human GnRH neuron transcriptome during developmental differentiation. Gonadotropin-releasing hormone (GnRH) neurons in the hypothalamus govern t...

ey0016.3-13 | Graves’ Disease | ESPEYB16

3.13. Adjuvant rituximab, a potential treatment for the young patient with Graves' hyperthyroidism (RiGD): study protocol for a single-arm, single-stage, phase II trial

M Cole , AM Hynes , D Howel , L Hall , M Abinun , A Allahabadia , T Barrett , K Boelaert , AJ Drake , P Dimitri , J Kirk , N Zammitt , S Pearce , T Cheetham

To read the full abstract: BMJ Open. 2019;9:e024705.This protocol paper describes an innovative phase II trial to study the effect of a single low dose of adjuvant rituximab (a chimeric anti-B-cell monoclonal antibody targeting the surface molecule CD20) compared to classical carbimazole therapy in adolescents and young adults with Graves’ disease. Carbimazole treatment will be stop...

ey0016.5-19 | Basic Science - Mineral Metabolism | ESPEYB16

5.19. Eldecalcitol causes FGF23 resistance for Pi reabsorption and improves rachitic bone phenotypes in the male Hyp mouse

I Kaneko , H Segawa , K Ikuta , A Hanazaki , T Fujii , S Tatsumi , S Kido , T Hasegawa , N Amizuka , H Saito , KI Miyamoto

Abstract: Endocrinology, Volume 159, Issue 7, July 2018, Pages 2741–2758In brief: Eldecalcitol, a long acting active vitamin D3 analogue with lower affinity for vitamin D receptor and resistance to inactivation by vitamin D 24-hydroxylase, causes FGF23 resistance. This leads to complete restoration of renal phosphate transport and NaPi-2a protein levels and improves ra...